https://www.live-feeds.com/feed/pharma-major-novartis-falls-10-after-three-drug-trial-setbacksContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/pharma-major-novartis-falls-10-after-three-drug-trial-setbackshttps://www.live-feeds.com/feed/pharma-major-novartis-falls-10-after-three-drug-trial-setbacks#u67059Sun, 13 Sep 2026 14:05:25 +0000Pharmaceutical major Novartis faces mounting pressure after experimental treatments missed clinical targets, including a late-stage study for the rare muscle-wasting condition myotonic dystrophy type 1. The experimental therapy del-desiran failed to demonstrate a statistically significant improvement over placebo regarding its primary endpoint, video hand opening time. This latest setback follows a sequence of adverse pipeline developments. In response to the clinical failures, a major shareholder, Artisan Partners, demanded a board shake-up at the Swiss drugmaker.Why it mattersThe recent clin https://www.live-feeds.com/feed/pharma-major-novartis-falls-10-after-three-drug-trial-setbackshttps://www.live-feeds.com/feed/pharma-major-novartis-falls-10-after-three-drug-trial-setbacks#u63658Thu, 10 Sep 2026 07:10:45 +0000Pharmaceutical major Novartis dropped 10 percent, heading toward its worst day on record, following a sequence of three pipeline and drug trial setbacks within a single week. The latest blow involves a dystrophy drug from the twelve billion dollar Avidity acquisition falling short in a Phase 3 rare muscle disease study. This third consecutive failure has triggered heavy share sell-offs across international markets as investors absorb the cumulative impact of these clinical developments.Why it mattersThe steep market reaction reflects deep concern over the commercial viability of a high-value c